Economic Evaluation of Nimesulide Versus Diclofenac in the Treatment of Osteoarthritis in Greece
Objective: To evaluate, from a social security system perspective, the economic consequences of treating rheumatic diseases with nimesulide or diclofenac. Design: Cost-minimisation analysis was used to estimate the incremental direct medical cost and the cost of gastrointestinal adverse events for 15 days' treatment with nimesulide compared with diclofenac. Cumulative incidence of adverse events was calculated through meta-analysis of the results of double-blind randomised clinical trials. The therapeutic pathway for ambulatory care resource use was determined by a panel of experts, and direct hospital costs were estimated from a sample of 43 patients. Main outcome measures and results: The 15-day treatment cost with nimesulide was 35.9% lower compared with diclofenac due to the lower incidence of adverse events. Our analysis showed that nimesulide generated a cost saving of $US20.98 per patient depending on the dosage of diclofenac used.
In order to set up a list of libraries that you have access to,
you must first login
or sign up.
Then set up a personal list of libraries from your profile page by
clicking on your user name at the top right of any screen.